Daniel Lee headshot
DL

Daniel W. "Trey" Lee

Assistant Professor
Director Pediatric Hematopoietic Stem Cell Transplantation & Immunotherapy
Unit: School of Medicine
Department: Department of Pediatrics
Office location and address
101 Hospital Dr
Charlottesville, Virginia 22903
Education
Washington & Lee University, BS Chemistry
University of Texas at Houston School of Medicine, MD
Residency, University of Texas at Houston
Fellowship, National Cancer Institute; Johns Hopkins
Biography

Dr. Daniel “Trey” Lee is a pediatric hematologist/oncologist, Assistant Professor, and the Director of the Pediatric Hematopoietic Stem Cell Transplant (HSCT) and Immunotherapy program at the University of Virginia.  He graduated from Washington & Lee University before heading to the University of Texas at Houston and MD Anderson Cancer Center for medical school, postdoctoral fellowship, and pediatrics residency.  He joined UVA in May 2016 after serving three years on faculty at the Pediatric Oncology Branch, National Cancer Institute where, in addition to Johns Hopkins University, he did his fellowship training.  He is a physician-scientist and clinical trial expert, particularly in Chimeric Antigen Receptor (CAR) T-cell therapies, a field in which he is internationally known.  He developed and led one of the first CD19-CAR T-cell trials in the world for children with leukemia/lymphoma.  In collaboration with other investigators, Dr. Lee established the first definition, grading and management standards for cytokine release syndrome (CRS), which was widely adopted internationally.  He has since led a larger, international group in developing an updated CRS and neurotoxicity consensus manuscript and published a book serving as a practical guide for CAR T-cell therapy.   He is currently building new HSCT and CAR T-cell programs at UVA, using his laboratory to design and develop new CARs before taking them into clinical trials for both pediatric and adult malignancies.  In another first for Virginia, these new CAR T-cell products will be manufactured in UVA’s new cell manufacturing facility (cGMP) where Dr. Lee also takes a leadership role. 

Development of a self-regulating feedback system of Chimeric Antigen Receptor T cell activity in response to specific circulating toxicity-associated inflammatory mediators
Source: The V Foundation for Cancer Research
January 01, 2022 – January 01, 2023
MD-PEDT-A Phase 1/2 Multi-Center Study Evaluating the
Source: Kite Pharma, Inc.
January 25, 2017 – June 30, 2022
American Cancer Society- Institutional Research Grant
Source: American Cancer Society
January 01, 2017 – June 19, 2021
Rapid Development of Chimeric Antigen Receptors (CARs) for DIPG
Source: The Childhood Brain Tumor Foundation
September 03, 2018 – September 02, 2019
MD-PEDT Developing Chimeric Receptor Cell Therapies for Pediatric Malignancies
Source: St. Baldrick's Foundation
July 01, 2016 – June 30, 2018
Bringing Cancer Immunotherapies to the Children of Virginia
Source: St. Baldrick's Foundation
January 01, 2017 – June 30, 2018

1994                 Yoshiyama Award for Exemplary Service to the Community, The Hitachi Foundation

2008 – 2012   NIH Intramural Loan Repayment Competitive Award

2009                 Travel Award, American Society of Hematology Annual Meeting

2011                 Abstract Achievement Award, Inclusion in 2011 Highlights of ASH, American Society of Hematology Annual Meeting

2012 – 2018   St. Baldrick’s Foundation Scholar (Young Investigator) Award

2018                 Best Paper of the Year Award, Cytometry B Clinical Cytometry

2018                 Top 10 Clinical Research Achievement Award, Clinical Research Forum

2018 – 2021   V Foundation Scholar Award